Immune Cell

Regulatory T cell

Regulatory T cells (Treg)” play a crucial role in maintaining immune homeostasis and tolerance by suppressing immune responses.
These lymphocytes inhibit T cell proliferation and cytokine production, thus preventing autoimmune reactions.
Our method involves evaluating the efficacy of an anticancer agent by treating a mixture of tumor organoids, cytotoxic T cells (CD8+ T cells), and regulatory T cells (Tregs) with the anticancer drug or drug candidate.


Price	7500€+ Login to see price
Organism	Human
Product Type	Organoid + T cell + Regulatory T cell
Tissue	Adaptive
Disease	–

Applications

Cancer Organoid

Colorectal Cancer

Non-Small Cell Lung Cancer

Pancreatic Cancer

Breast Cancer

Cholangiocarcinoma

Gastric Cancer

Ovarian Cancer

Description

Characteristics

A drug evaluation solution co-culturing Treg, T cells, and cancer organoids allows for the assessment of drugs that can regulate Treg. This provides a drug evaluation solution capable of evaluating drugs that can modulate Treg.

Process

We aimed to develop tumor organoids with a tumor microenvironment and use them as a solution for drug evaluation.
For this, we created a system where tumor organoids, cytotoxic T cells, and regulatory T cells were co-cultured at specific ratios.
We activated T cells from PBMCs, then separately cultured and counted cytotoxic T cells and regulatory T cells.
Finally, after establishing the co-culture system at designated ratios, we measured the efficacy of immuno-oncology drugs.

	Cell nr	Gated %
CD8+	47,600	–

	Cell nr	Gated %
CD8+ CD25+ FoxP3	7,500	–

We compared the commonly used immuno-oncology drug atezolizumab with candidate.
When T cells alone or cytotoxic T cells and regulatory T cells were added, we examined the effect of each immuno-oncology drug.
Only in the case of co-culture with regulatory T cells, the efficacy of the drug decreased rapidly.
This is a result of regulatory T cells inducing T cell suppression during co-culture.
These results prove that our solution can most similarly simulate the tumor microenvironment consisting of tumor organoids, cytotoxic T cells and regulatory T cells.
Screen and accurately evaluate anti-cancer drugs targeting regulatory T cells using our validated solution that closely resembles the in vivo tumor microenvironment.